ATLANTA & CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today presented, for the first time, results of studies on its novel multi-targeted kinase inhibitor, AP24534, showing efficacy and oral dosing flexibility in animal models of chronic myeloid leukemia (CML), including forms of CML caused by clinically relevant variants of the target protein, Bcr-Abl. Further, AP24534 demonstrated potent inhibition of selected additional kinase targets – the receptors for vascular endothelial growth factors (VEGFR), fibroblast growth factors (FGFR) and angiopoietin (Tie2) that control angiogenesis, and Flt3 kinase that plays a critical role in the pathogenesis of acute myeloid leukemia (AML). These findings support the broad potential of AP24534 not only in drug-resistant CML, but also in other hematological cancers, such as AML, and various solid tumors. These data were presented today at the 49th American Society of Hematology Annual Meeting.
